医学
内科学
胃肠病学
淋巴瘤
细胞因子释放综合征
CD19
外科
B细胞
耐火材料(行星科学)
滤泡性淋巴瘤
化疗
临床试验
存活率
美罗华
CD20
肿瘤科
弥漫性大B细胞淋巴瘤
癌症研究
临床研究阶段
嵌合抗原受体
免疫疗法
癌症
物理
天体生物学
作者
Yajing Zhang,Yao Wang,Yang Liu,Chuan Tong,Chunmeng Wang,Yelei Guo,Dongdong Ti,Qingming Yang,Shen Qiao,Zhiqiang Wu,Weidong Han
出处
期刊:Leukemia
[Springer Nature]
日期:2021-07-16
卷期号:36 (1): 189-196
被引量:14
标识
DOI:10.1038/s41375-021-01345-8
摘要
Increasing the remission rate and reducing the recurrence rate can improve the clinical efficacy of chimeric antigen receptor (CAR) T cell therapy in recurrent/refractory non-Hodgkin lymphoma (r/rNHL). In this open-label, single-arm phase I/II trial, 87 patients with r/rNHL, including 58 patients with aggressive diffuse large B-cell lymphoma and 24 with high tumour burden, received an infusion at doses of 0.5 × 106-8 × 106 TanCAR7 T cells per kilogram of body weight after conditioning chemotherapy. The best overall response rate was 78% (95% confidence interval [CI], 68-86); response rates were consistent across prognostic subgroups. The median follow-up was 27.7 months. The median progression-free survival was 27.6 months (95% CI, 11 to not reached). Cytokine release syndrome (CRS) occurred in 61 patients (70%) with 60% of cases being grade 1 or 2 and 10% being grade 3 or greater. Grade 3 CAR T cell-related encephalopathy syndrome (CRES) occurred in 2 patients (2%). Two patients died from treatment-associated severe pulmonary infection, and one died from CRS-related pulmonary injury between 1 and 3 months post infusion. Long-term remissions were observed following the use of TanCAR7 T cells in r/rNHL with a safety profile that included CRS but few cases of CRES.
科研通智能强力驱动
Strongly Powered by AbleSci AI